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Arterial stiffening, a measure of subclinical arterial injury, is associated with cardiovascular disease (CVD) and 
mortality1–4 in a variety of populations, including in type 2 dia-
betes mellitus (T2DM).5 Moreover, the age-related increase 
in arterial stiffness is steeper in individuals with T2DM com-
pared with individuals without.6,7 The exact mechanisms 
behind the development of arterial stiffness and subsequent 
CVD are not completely understood. The increased accumula-
tion of advanced glycation end products (AGEs) on long-lived 
proteins, such as collagen in the arterial wall, may lead to the 
formation of cross links, and in the arterial wall, may subse-
quently lead to increased stiffening.8 Additionally, AGEs have 
been linked to arterial stiffness via other mechanisms like 
intracellular protein glycation or receptor for AGE (RAGE) 
activation.9 AGEs are thus thought to play a crucial role in the 
development of arterial stiffness, especially in T2DM.
Indeed, several studies found an association between mea-
sures of AGE accumulation and arterial stiffening.10–20 Only one 
case–control study investigated this association in individuals 
with T2DM. This study found no association between serum 
pentosidine and heart-brachial pulse-wave velocity or brachial-
ankle pulse-wave velocity after adjustment for renal func-
tion.15 However, it did not take other potential confounders into 
account. Moreover, the measurement of skin autofluorescence 
(SAF) has recently emerged as an estimate of AGE accumula-
tion in skin tissue21 and may thereby be a better estimate of tissue 
AGE accumulation than plasma AGEs. To date, no study has 
investigated the association between SAF and plasma AGEs and 
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carotid to femoral pulse-wave velocity (cfPWV) or pulse pres-
sure, both measures of aortic stiffening, in a population-based 
setting, including individuals with normal glucose metabolism 
(NGM), impaired glucose metabolism (IGM), and T2DM.
In view of these considerations, the aims of our study 
were, first, to evaluate the independent association between 
SAF and plasma AGEs on the one hand and measures of arte-
rial stiffening, ie, cfPWV, central pulse pressure, and 24-hour 
ambulatory pulse pressure, on the other. Second, to examine 
whether these associations differed between individuals with 
NGM, IGM, or T2DM.
Methods
Study Population and Design
In this study, we used data from The Maastricht Study, an observa-
tional prospective population-based cohort study. The rationale and 
methodology have been described previously.22 In brief, the study 
focuses on the cause, pathophysiology, complications, and comor-
bidities of type 2 diabetes mellitus (T2DM) and is characterized by 
an extensive phenotyping approach. Eligible for participation were 
all individuals aged between 40 and 75 years and living in the south-
ern part of the Netherlands. Participants were recruited through mass 
media campaigns and from the municipal registries and the regional 
Diabetes Patient Registry via mailings. Recruitment was stratified 
according to known T2DM status for reasons of efficiency. The pres-
ent report includes cross-sectional data from the first 866 participants, 
who completed the baseline survey between November 2010 and 
March 2012. The examinations of each participant were performed 
within a time window of 3 months. The study has been approved by 
the institutional medical ethical committee (NL31329.068.10) and 
the Netherlands Health Council under the Dutch “Law for Population 
Studies” (Permit 131088-105234-PG). All participants gave written 
informed consent. From the initial 866 individuals in included in this 
study, we excluded individuals with type 1 diabetes mellitus (n=4).
Skin Autofluorescence
All participants were asked to refrain from smoking and caffeine at 
least 3 hours before the measurements. A light meal (breakfast or 
lunch), low in fat content, was allowed. SAF was measured with 
the AGE Reader (DiagnOptics Technologies BV, Groningen, The 
Netherlands). The AGE reader is a desktop device that uses the char-
acteristic fluorescent properties of certain AGEs to estimate the level 
of AGE accumulation in the skin. Technical details of this noninva-
sive method have been described more extensively elsewhere.21 In 
short, the AGE Reader illuminates a skin surface of 4 cm2 guarded 
against surrounding light, with an excitation wavelength range of 300 
to 420 nm, with a peak excitation of 370 nm. SAF was calculated as 
the ratio between the emission light from the skin in the wavelength 
range of 420 to 600 nm (fluorescence) and excitation light that is 
reflected by the skin (300–420 nm), multiplied by 100 and expressed 
in arbitrary units. Participants were asked not to use any sunscreen 
or self-browning creams on their lower arms within 2 days before 
the measurement. SAF was measured at room temperature in a semi-
dark environment, whereas participants were at rest in a seated posi-
tion. The inner side of the forearm ≈4 cm below the elbow fold of a 
participant was positioned on top of the device, as described by the 
manufacturer. The mean of 3 consecutive measurements was used in 
the analyses. Reproducibility was assessed in 14 individuals without 
diabetes mellitus (6 men; 32.2±7.1 years). The intraclass correlation 
coefficient of 3 intraindividual consecutive SAF measurements was 
0.83 (95% confidence interval [CI], 0.65–0.94). SAF was calculated 
offline by automated analysis using AGE Reader software, version 
2.3, and was observer independent. There were no significant differ-
ences between fasting and nonfasting measurements (mean differ-
ence=0.01 arbitrary units; P=0.73). Reproducibility in individuals 
with T2DM has been evaluated previously21 with an overall Altman 
error percentage of 5.03% for measurements taken over a single day. 
Skin pigmentation is known to influence the measurement of SAF.23 
Therefore, in participants with dark-colored skin with a reflectance of 
6% to 10%, a validated reflectance-dependent correction was made 
by the software.23 Measurements in participants with dark-colored 
skin and a mean reflectance below 6% are considered unreliable and 
are therefore not used to calculate SAF by the software. Therefore, 
these participants were automatically excluded (n=1). Additionally, a 
single SAF value above 10 arbitrary units was considered as unreli-
able; these individual measurements (n=3) were manually excluded, 
and the mean of the remaining 2 measurements was used in analyses.
Analysis of Protein-Bound AGEs and Lysine in 
Plasma
Plasma AGEs were measured in EDTA samples obtained from 
fasting venous blood, which were stored at −80 °C until analysis. 
Protein-bound pentosidine was quantified using high-performance 
liquid chromatography with fluorescence detection, as described 
in detail elsewhere.24 Intra- and interassay coefficients of varia-
tion, as analyzed in this study, were 6.5% and 7.8% for pentosidine, 
respectively. Protein-bound Nε-(carboxymethyl)lysine (CML) and 
Nε-(carboxyethyl)lysine (CEL) and lysine were quantified using 
ultra-performance liquid chromatography tandem mass-spectrome-
try.25 Intra- and interassay coefficients of variation were 4.5% and 
6.7% for CML, 6.2% and 10.3% for CEL, and 5.0% and 5.3% for 
lysine. Concentrations of protein-bound pentosidine, CML, and CEL 
were adjusted for levels of lysine and expressed as nmol/mmol lysine.
Carotid to Femoral Pulse-Wave Velocity and 
Central Pulse Pressure
As described previously,26 cfPWV and central pulse pressure (cPP) 
were assessed noninvasively by means of applanation tonometry. All 
measurements (≈45 minutes) were done by trained vascular techni-
cians unaware of the participants’ clinical or diabetes mellitus status. 
Measurements took place in a quiet, temperature-controlled room 
(21–23°C) and were performed in supine position, after 10 minutes 
of rest. Participants were asked to refrain from smoking and drink-
ing coffee or tea or alcohol beverages 3 hours before the study. 
Participants were allowed to have a light meal (breakfast and lunch). 
Talking or sleeping was not allowed during the examination. A 3-lead 
ECG was recorded continuously during the measurements to facili-
tate automatic signal processing. In addition, brachial systolic, dia-
stolic, and mean arterial pressure were determined repeatedly with 
a 5-minute interval, using an oscillometric device (Accutorr Plus, 
Datascope, Inc, Montvale, NJ), and the average of these measure-
ments was calculated. cfPWV was determined according to recent 
guidelines27 with the use of applanation tonometry (SphygmoCor, 
Atcor Medical, Sydney, Australia). Pressure waveforms were deter-
mined at the right common carotid and right common femoral arter-
ies. The difference in the time of pulse arrival from the R-wave of 
the ECG between the 2 sites (transit time) was determined with the 
intersecting tangents algorithm. The pulse wave travel distance was 
calculated as 80% of the direct straight distance (measured with an 
infantometer) between the 2 arterial sites. cfPWV was defined as trav-
elled distance/transit time. cPP was determined by radial applanation 
tonometry (Sphygmocor, Atcor Medical, Australia).28 The median of 
3 consecutive cfPWV and cPP recordings were used in the analyses.
Glucose Metabolism Status
As described previously,22 to determine glucose metabolism, all par-
ticipants (except those who used insulin) underwent a standardized 
7-point oral glucose tolerance test after an overnight fast. Blood sam-
ples were taken at baseline and at 15, 30, 45, 60, 90, and 120 minutes 
after ingestion of a 75 g glucose drink. For safety reasons, partici-
pants with a fasting glucose level above 11.0 mmol/L, as determined 
by a finger prick, did not undergo the oral glucose tolerance test. For 
these individuals (n=13), fasting glucose level and information about 
diabetes mellitus medication use were used to determine glucose 
metabolism status. Glucose metabolism was defined according to the 
WHO 2006 criteria into normal glucose tolerance, impaired fasting 
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glucose, impaired glucose tolerance, and T2DM.29 For this study, we 
defined having either impaired fasting glucose or impaired glucose 
tolerance as IGM.
For method description on 24-hour ambulatory blood pressure, pe-
ripheral neuropathy, diabetic nephropathy, and other covariates, we 
refer to the online-only Data Supplement.
Statistical Methods
Analyses were conducted using SPSS version 21 for Windows. 
Comparisons of baseline characteristics between groups were made 
by use of ANOVA or χ2 tests. Variables with a skewed distribution 
were log10 transformed before analysis. We used standardized mul-
tiple linear regression analysis to evaluate the association between 
SAF and plasma AGEs on the one hand and cfPWV, cPP, and 24-hour 
ambulatory pulse pressure (aPP) on the other, which enabled us to 
adjust for possible confounding factors. As presented in each table, 
we included all available data in the analyses to avoid selection bias. 
We investigated whether or not these associations differed between 
individuals with different glucose metabolism status by adding inter-
action terms in our models (eg, the product of (1) SAF or plasma AGE 
levels and (2) glucose metabolism status). P values <0.05 were con-
sidered statistically significant, except for interaction terms, where a 
P value <0.10 was considered statistically significant.
Results
General Characteristics
Table 1 shows the general characteristics, stratified accord-
ing to tertiles of cfPWV. Data on SAF were available in 831 
individuals, plasma AGEs in 843, cfPWV data in 820, and 
cPP data in 828 individuals. Missing data were predomi-
nantly caused by device nonavailability or technical prob-
lems. Plasma AGEs were measured in blood samples, which, 
for the missing cases, were mostly not available because of 
difficulties in blood withdrawal. As a sensitivity analysis, we 
additionally performed all analyses in a data set where miss-
ing values were imputed by multiple imputation using SPSS. 
These additional analyses were not materially different from 
our original analyses. The percentage of individuals with IGM 
or T2DM, peripheral sensory neuropathy, albuminuria, hyper-
tension, antihypertensive or lipid-modifying or diabetes medi-
cation, and a history of CVD was higher in the higher cfPWV 
tertiles. Also, with higher cfPWV tertile, the percentage of 
men and former smokers was higher, as were age, diabetes 
mellitus duration, glycohemoglobin, waist circumference, 
total-to-high-density lipoprotein cholesterol ratio and triglyc-
erides; eGFR was lower with higher cfPWV. SAF and plasma 
pentosidine level were higher with higher cfPWV, as were 
mean arterial pressure and heart rate (Table 1). For the general 
characteristics stratified by glucose metabolism status, please 
see Table S1 in the online-only Data Supplement.
Associations Between AGE Accumulation and 
Aortic Stiffening
Both SAF (sβ 0.09; 95% CI, 0.03–0.16) and plasma pentosi-
dine (sβ 0.09; 95% CI, 0.03–0.16) were significantly associ-
ated with higher cfPWV, after adjustment for age, sex, glucose 
metabolism status, average mean arterial pressure, and heart 
rate obtained during cfPWV measurement; waist circumfer-
ence; smoking; antihypertensive, lipid-modifying, and dia-
betes mellitus medication use; eGFR; total-to-high-density 
lipoprotein cholesterol ratio; triglycerides; and a history of 
cardiovascular disease (Table 2). These associations were 
more pronounced in individuals with T2DM (SAF: sβ 0.13; 
95% CI, −0.01 to 0.28; pentosidine: sβ 0.12; 95% CI, -0.02 
to 0.26, P alues for interaction <0.10) (Figure). The associa-
tion between SAF and cfPWV was also more pronounced 
in individuals with IGM compared to those with NGM (sβ 
0.13, 95%-CI -0.05 to 0.31), but without significant interac-
tion (P=0.322; Figure). SAF (sβ 0.08; 95% CI; 0.01–0.15) 
and plasma pentosidine (sβ 0.07; 95% CI, 0.01–0.13) showed 
positive and similar significant associations with cPP after 
adjustment for age, sex, glucose metabolism status, average 
24-hour mean arterial pressure, average 24-hour heart rate, 
waist circumference, smoking, antihypertensive or lipid-mod-
ifying or diabetes medication use, eGFR, total-to-high-den-
sity lipoprotein cholesterol ratio, triglycerides, and a history 
of cardiovascular disease (Table 2). The associations between 
SAF and AGEs on the one hand and cPP on the other were 
not different for different glucose metabolism status (P for 
interaction >0.10; Figure). SAF (sβ 0.06; 95% CI, −0.01 to 
0.12), plasma pentosidine (sβ 0.05; 95% CI, −0.01 to 0.11), 
and plasma CML (sβ 0.06; 95% CI, −0.01 to 0.12) showed 
positive, nonsignificant associations with aPP (Table S2).
Influence of Previous CVD, Peripheral Neuropathy, 
and Diabetic Nephropathy on the Associations 
Between AGE Accumulation and Aortic Stiffening
The inclusion of individuals with previous CVD in our 
analysis may have influenced the observed associations 
between measures of AGE accumulation and arterial stiff-
ness. However, exclusion of individuals with previous CVD 
did not materially change the associations between SAF and 
plasma AGEs on the one hand and cfPWV and cPP on the 
other (Figure S1). Furthermore, additional adjustment for 
PSN and albuminuria, as markers of microvascular disease, 
did not materially change the associations between SAF and 
plasma AGEs on the one hand and cfPWV and cPP on the 
other (Table S3).
Discussion
This study had 3 main findings. First, we found that higher 
SAF and plasma pentosidine were independently associated 
with higher cfPWV and cPP. Second, in analyses stratified 
for glucose metabolism status, we found that the associa-
tions between SAF and plasma pentosidine on the one hand 
and cfPWV on the other were more pronounced in individu-
als with T2DM. This is the first population-based study that 
describes an association between SAF and measures of aortic 
stiffening in individuals with NGM, IGM, and T2DM. Our 
results are in agreement with previous studies, which demon-
strated that skin AGEs are associated with arterial stiffening 
in type 1 diabetes mellitus,16 heart disease, and 10 end-stage 
renal disease11 and in the elderly.12,19 We found relatively small 
standardized regression coefficients in these associations. In 
comparison, sβs and 95% CIs of the associations between 
mean arterial pressure and age on the one hand and cfPWV 
on the other were 0.37 (0.31–0.43) and 0.31 (0.24–0.38), 
respectively, in our study. However, the fact that these coef-
ficients were statistically significant suggests that the associa-
tion between the different measures of AGEs and measures of 
arterial stiffness, albeit small, indeed reflect a true association 
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between AGE accumulation and aortic stiffening. In fact, 
the effect size on an association does not necessarily reflect 
the biological importance of the pathophysiological process. 
Therefore, these results provide us with more insight into the 
pathophysiology of arterial stiffening and the possible role of 
AGEs herein.
AGEs are thought to affect vascular tissue via distinct path-
ways. First, certain AGEs, for example, pentosidine, are able 
to form cross-links between extracellular matrix proteins such 
as collagen in the arterial wall, which may directly result in a 
decrease in vascular elasticity and an increase in arterial stiff-
ening.8,13,30 Second, other AGEs, for example, CEL, are able 
to affect cell function via intracellular glycation of proteins, 
altering the function of these proteins,9 for example, leading 
to the quenching of nitric oxide resulting in increased smooth 
muscle cell tone, which contributes to arterial stiffening.31 
Third, some AGEs, for example, CML, are known to bind to 
the RAGE, inducing receptor-mediated cell activation and low-
grade inflammation,32,33 which in its turn may promote arterial 
stiffening via for example, MMPs, endothelial dysfunction that 
elevates smooth muscle tone, and a reduction of endothelial 
flow–mediated dilation.31 In addition to an association between 
SAF and measures of aortic stiffening, we found a positive 
association between plasma pentosidine and aortic stiffening. 
Table 1. General Characteristics of the Maastricht Study Participants
Characteristics
Tertiles of Carotid to Femoral Pulse-Wave Velocity (n=820)
First Tertile (n=273); 
(4.8–7.8 m/s)
Second Tertile (n=274); 
(7.8–9.4 m/s)
Third Tertile (n=273);  
(9.4–20.2 m/s) P Value
NGM/IGM/T2DM, % 72/11/17 57/18/25 35/20/45 <0.001
Age, y 55±8 60±8 65±6 <0.001
Sex (number of men/women) 122/151 159/115 165/108 <0.001
Diabetes mellitus duration, y 4 (2–7) 7 (2–11) 8 (5–13) <0.001
HbA1c, % 5.8±0.7 5.9±0.6 6.3±1.0 <0.001
HbA1c, mmol/mol 40±8 41±7 45±11 <0.001
Smoking, never/former/current, % 37/45/18 28/56/16 29/57/14 0.052
Waist circumference, cm 93±13 97±13 100±13 <0.001
Total-to-HDL cholesterol ratio 4.0±1.2 4.4±1.2 4.2±1.3 0.006
Triglycerides, mmol/L 1.1 (0.8–1.6) 1.2 (0.9–1.8) 1.4 (1.0–2.0) <0.001
eGFR
CKD-EPI
, mL/min/1.73 m2 90±13 84±14 80±15 <0.001
Albuminuria (normo/micro/macro), % 95/4/1 94/5/1 88/11/1 0.008
Peripheral sensory neuropathy, n (%) 9 (4) 16 (8) 40 (22) <0.001
Hypertension, n (%) 97 (36) 157 (57) 217 (80) <0.001
Antihypertensive medication, n (%) 74 (27) 108 (39) 141 (52) <0.001
Lipid-modifying medication, n (%) 68 (25) 92 (34) 136 (50) <0.001
Diabetes mellitus medication, n (%) 41 (15) 57 (21) 88 (32) <0.001
History of CVD, n (%) 33 (13) 46 (17) 60 (24) 0.003
SAF, AU 2.55±0.51 2.70±0.50 2.88±0.55 <0.001
Pentosidine, nmol/mmol LYS 0.44 (0.37–0.53) 0.47 (0.38–0.56) 0.49 (0.40–0.61) <0.001
CML, nmol/mmol LYS 74.8±14.4 74.7±14.7 73.6±15.1 0.586
CEL, nmol/mmol LYS 34.3±10.8 33.2±9.3 34.8±10.6 0.183
cfPWV, m/s 6.98±0.59 8.60±0.47 11.4±1.8 …
MAP, mm Hg 92±8 98±9 103±10 <0.001
Heart rate, bpm 62±8 63±8 65±9 <0.001
Central pulse pressure, mm Hg 38 (33–47) 45 (38–55) 55 (44–68) <0.001
Ambulatory 24-h PP, mm Hg 41±7 44±8 51±9 <0.001
Ambulatory 24-h MAP, mm Hg 90±7 93±8 96±9 <0.001
Ambulatory 24-h heart rate, bpm 70±8 69±9 71±9 0.014
Data are presented as mean±SD or as median (IQR), unless otherwise indicated. AU indicates arbitrary units; CEL, N(epsilon)-(carboxyethyl)lysine; CML, 
N(epsilon)-(carboxymethyl)lysine; cfPWV, carotid to femoral pulse-wave velocity; CVD, cardiovascular disease; DBP, diastolic blood pressure; eGFR
CKD-EPI
, 
estimated glomerular filtration rate; HbA1c, glycohemoglobin; HDL, high-density lipoprotein; IGM, impaired glucose metabolism; MAP, mean arterial pressure; 
NGM, normal glucose metabolism; SAF, skin autofluorescence; SBP, systolic blood pressure; and T2DM, type 2 diabetes mellitus.
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One previous study found no association between serum pen-
tosidine and heart-brachial PWV or brachial-ankle PWV after 
adjustment for renal function.15 However, this was based on 
a small, case–control study. Next, we found no association 
between plasma CML and CEL and cfPWV or cPP. This is 
in contrast with other studies that demonstrated an association 
between the plasma AGEs, CML, and CEL, and arterial stiff-
ening in other populations.13,14,17–19 In the case of CML, it has 
recently been described that the trapping of CML by the RAGE 
in adipose tissue causes a decrease in AGE plasma levels in 
individuals with T2DM.34 Therefore, plasma CML may not 
be a good reflection of CML accumulation in tissues in indi-
viduals with T2DM. This may explain why we did not find an 
association between plasma CML and aortic stiffening in our 
population. We do not have a clear explanation why we found 
no association between CEL and aortic stiffening, whereas 
others, in different populations, did. Because we only found an 
association between plasma pentosidine and cfPWV and cPP, 
this could indicate that cross-linking of AGEs, and not, or to 
a lesser extent intracellular glycation or RAGE activation, is 
the predominant pathway through which AGEs lead to aortic 
stiffening in T2DM. However, we cannot exclude the possi-
bility that plasma pentosidine is simply a better reflection of 
the detrimental effects of AGEs on the vessel wall in general. 
Taken together, the results of our study combined with previous 
research, support the hypothesis that AGE accumulation, and 
in particular AGE cross-linking, may play a role in the devel-
opment of arterial stiffening in individuals with NGM, IGM, 
and T2DM. We found nonsignificant positive associations 
between SAF, plasma pentosidine, and CML on the one hand 
and aPP on the other. These results may be explained by the 
fact that cfPWV, as the gold-standard measurement of aortic 
stiffening,28 and cPP are more precise markers of arterial stiff-
ening compared with aPP. The associations between both SAF 
and pentosidine on the one hand and cfPWV on the other were 
more pronounced in individuals with T2DM. Additionally, 
the association between SAF and cfPWV was also more pro-
nounced in individuals with IGM. This could be caused by the 
fact that in individuals with higher AGE levels, there is not only 
more cross-linking but also more RAGE activation with sub-
sequent low-grade inflammation, and more intracellular glyca-
tion. As discussed above, these mechanisms could both lead to 
a further increase in arterial stiffening. Additionally, we cannot 
exclude the possibility that for individuals with NGM, having 
less variation in AGE accumulation and arterial stiffening com-
pared with individuals with T2DM, it is more difficult to find 
an association between the 2. We excluded the possibility that 
the inclusion of individuals with previous CVD or microvas-
cular disease influenced our findings, by repeating analyses in 
individuals without CVD only and by adjusting for markers of 
microvascular disease, after which we found similar results. 
When we additionally adjust the association between SAF and 
plasma AGEs on the one hand and cfPWV on the other for fast-
ing glucose level, we find smaller sβ (sβ 0.06; 95% CI, −0.01 
to 0.14 for SAF, and sβ 0.05; 95% CI, −0.02 to 0.11 for pento-
sidine), and associations were no longer significant. This could 
mean that part of the association between AGE measurements 
and arterial stiffening is explained by a difference in glucose 
Table 2. Associations Between Measures of AGE Accumulation and cfPWV or cPP
AGEs Model
Carotid to Femoral Pulse-Wave Velocity Central Pulse Pressure
sβ 95% CI P Value sβ 95% CI P Value
SAF 1 0.10 0.03 to 0.17 0.006 0.06 −0.02 to 0.14 0.114
2 0.11 0.05 to 0.17 0.001 0.07 0.00 to 0.14 0.050
3 0.10 0.03 to 0.17 0.004 0.08 0.01 to 0.15 0.018
Plasma 
pentosidine
1 0.08 0.02 to 0.15 0.011 0.09 0.03 to 0.16 0.007
2 0.08 0.02 to 0.14 0.005 0.09 0.03 to 0.15 0.003
3 0.10 0.04 to 0.16 0.002 0.07 0.01 to 0.13 0.025
Plasma CML 1 −0.01 −0.07 to 0.06 0.870 0.05 −0.02 to 0.12 0.135
2 0.00 −0.06 to 0.06 0.928 0.06 0.00 to 0.12 0.062
3 0.00 −0.06 to 0.07 0.895 0.04 −0.03 to 0.10 0.281
Plasma CEL 1 0.03 −0.04 to 0.09 0.393 −0.02 −0.09 to 0.05 0.561
2 0.03 −0.03 to 0.08 0.348 −0.02 −0.08 to 0.04 0.556
3 0.01 −0.04 to 0.07 0.643 0.00 −0.06 to 0.06 0.932
Model 1 is adjusted for age, sex, and glucose metabolism status. Model 2 is additionally adjusted for average mean arterial pressure. Model 3 is additionally 
adjusted for average heart rate, waist circumference, smoking, antihypertensive and lipid-modifying and diabetes medication use, eGFR, total-to-HDL cholesterol ratio, 
triglycerides, and a history of cardiovascular disease. There were 740 individuals (414 with NGM, 122 with IGM, and 203 with T2DM) included in the analyses between 
SAF and cfPWV, 752 individuals (417 with NGM, 122 with IGM, and 208 with T2DM) in the analyses between plasma AGEs and cfPWV, 726 individuals (401 with NGM, 
127 with IGM, and 208 with T2DM) included in the analyses between SAF and cPP and 739 (405 with NGM, 127 with IGM, and 207 with T2DM) individuals in the analyses 
between plasma AGEs and cPP. Standardized β, the standardized regression coefficient obtained with linear regression analyses, indicates the change in cfPWV or 
cPP (in SD) per 1 SD higher SAF or level of plasma advanced glycation endproducts, that is, plasma pentosidine, CML and CEL. AGE indicates advanced glycation 
end product; CEL, N(epsilon)-(carboxyethyl)lysine; cfPWV, carotid to femoral pulse-wave velocity; CI indicates confidence interval; CML, N(epsilon)-(carboxymethyl)
lysine; cPP, central pulse pressure; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; IGM, impaired glucose metabolism; NGM, normal glucose 
metabolism; SAF, skin autofluorescence; and T2DM, type 2 diabetes mellitus
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levels between GMS groups. Another explanation for these 
findings is that glucose is a marker in the same pathway as SAF 
and AGEs, which causes the regression coefficient to diminish. 
For this study, we used both SAF, an estimate of skin AGEs, 
and protein-bound AGEs in plasma to serve as a reflection of 
tissue AGEs. SAF is thought to reflect AGE accumulation and 
AGE cross-linking in the extracellular matrix of the vessel wall 
more accurately than plasma proteins, as plasma AGE levels 
are determined to a large extent by the half-life of plasma pro-
teins, which is significantly shorter than the half-life of long-
lived proteins in the skin and in vascular tissue.35 The fact that 
we found an association between SAF and aortic stiffening and 
not between plasma CML or CEL and aortic stiffening further 
supports this hypothesis, at least for plasma CML and CEL. 
As AGE accumulation may be involved in the development of 
arterial stiffening and CVD in individuals with T2DM, AGE-
lowering therapies may decrease the risk of CVD in individuals 
with T2DM. One of the well-studied, potential, anti-AGE ther-
apies is the cross-link breaker alagebrium (ALT-711). Indeed, 
it has been shown that alagebrium is able to reduce large artery 
stiffening in animal models.36 One double-blind randomized 
controlled trial correspondingly showed a decrease in pulse 
pressure and cfPWV in individuals who received alagebrium.37 
However, another double-blind randomized controlled trial 
Figure. Associations between measures of advanced glycation end product (AGE) accumulation and carotid to femoral pulse-wave 
velocity (cfPWV) or central pulse pressure (cPP) in individuals with normal glucose metabolism (NGM), impaired glucose metabolism 
(IGM), and type 2 diabetes mellitus (T2DM). Data are presented as standardized β (sβ) and 95% confidence interval. sβ is the 
standardized regression coefficient obtained with linear regression analyses, which indicates the change in cfPWV or cPP in SD per 1 
SD higher skin autofluorescence (SAF), level of plasma pentosidine, plasma Nε-(carboxymethyl)lysine (CML) or plasma Nε-(carboxyethyl)
lysine (CEL) in the total population, individuals with normal glucose metabolism (NGM), impaired glucose metabolism (IGM), or T2DM. 
The presented sβs are adjusted for age and sex, average mean arterial pressure and heart rate, waist circumference, smoking, 
antihypertensive and lipid-modifying and diabetes mellitus medication use, estimated glomerular filtration rate, total-to-high-density 
lipoprotein cholesterol ratio, triglycerides, and a history of cardiovascular disease. The displayed P values indicate the significance of 
interaction of glucose metabolism status in these associations.
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showed no treatment effects on cardiac function and exercise 
tolerance.38
Strengths of this study include the large and well-charac-
terized samples, the assessment of aortic stiffening and the 
use of state-of-the art techniques to measure multiple markers 
of glycation end products. Limitations of the study include, 
first, this cross-sectional design of the study; therefore, we 
cannot draw any conclusions about causality in the associa-
tion between AGE accumulation and aortic stiffening. Second, 
by stratifying for glucose metabolism status, we performed 
analyses in a smaller number of individuals, especially in the 
IGM group, which diminishes the power to detect an asso-
ciation. Third, as stated previously, we do not know whether 
and to what extent the different plasma AGEs reflect specific 
pathophysiological pathways, that is, cross-linking, intracel-
lular protein glycation, or RAGE activation, or are merely a 
reflection of AGE formation and vascular damage in general.
Perspectives
Arterial stiffening increases the risk of cardiovascular disease, 
especially among individuals with type 2 diabetes mellitus. 
We demonstrate that higher levels of SAF, plasma pentosi-
dine, and plasma CML were associated with more aortic stiff-
ening and that associations for cfPWV were more pronounced 
in individuals with T2DM. These results support the hypoth-
esis that AGE accumulation is involved in arterial stiffening 
in general, and, moreover, the accelerated arterial stiffening 
in individuals with T2DM. Prospective studies are needed. 
Assuming causality between AGEs and arterial stiffness, 
interference in the pathways of AGE accumulation might 
influence the development and progression of arterial stiffen-
ing, in particular in individuals with T2DM. Therefore, more 
large, specific, and well-designed studies are needed to eluci-
date their potential effect in humans, in particular individuals 
with T2DM.
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What Is New?
•	This study demonstrates in a population-based setting that higher levels 
of advanced glycation end products (AGEs), as measured with state-of-
the art techniques, were associated with more aortic stiffening and that 
this association was more pronounced in individuals with type 2 diabetes 
mellitus.
What Is Relevant?
•	Assuming causality between AGEs and arterial stiffening, interference in 
AGE accumulation may influence the development and progression of ar-
terial stiffening, in particular in individuals with type 2 diabetes mellitus.
Summary
AGEs were associated with more aortic stiffening. These data ar-
gued in favor of studying AGE-lowering therapies to decrease arte-
rial stiffening and the risk of cardiovascular disease.
Novelty and Significance
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Supplementary methods  
 
24-hour ambulatory blood pressure  
Ambulatory blood pressure was measured with ambulatory 24-hour BP monitoring 
(WatchBP O3, Microlife AG, Switzerland). Cuffs were applied to the participants’ 
nondominant arm. Measurements were programmed for every 15 minutes during 
daytime (08.00–23.00 hours) and every 30 minutes during the night (23.00–08.00 
hours), for a total of 24 hours. As quality criteria, mean 24-hour blood pressure 
measurements were only calculated if more than 14 valid measurements at daytime 
and more than 7 valid measurements at night were available, based on 
recommendations of the British Hypertension Society1. Mean 24-hour ambulatory 
pulse pressure (aPP, defined as aSBP-aDBP), 24-hour ambulatory heart rate, and 
24-hour ambulatory mean arterial pressure (MAP, defined as aDBP + (0.412 x aPP)) 
2 were calculated based on hourly averages 3. Data on aPP was available for 774 
individuals. Missing data were predominantly caused by device non-availability or 
technical problems. 
 
Measures of peripheral neuropathy and diabetic nephropathy 
Vibration perception threshold (VPT) was measured as a marker of peripheral 
neuropathy. VPT was assessed using a hand-held neurothesiometer (Horwell 
Scientific Laboratory Supplies, Nottingham, UK). After a test procedure on the 
participant’s elbow, VPT was tested three times at the distal phalanx of the hallux of 
the right and left foot. The minimum VPT at which the subject was aware of vibration 
sensation was recorded to the nearest 0.5 V, starting from 0.0 V with stimulation up 
to 50.0 V. The mean of the three measurements for the least sensitive foot was used 
in further analyses 4, 5. Peripheral sensory neuropathy (PSN) was defined as VPT 
≥25 V (2). To assess urinary albumin excretion, participants were requested to collect 
two 24-hour urine collections. Urinary albumin concentration was measured with a 
standard immunoturbidimetric assay by an automatic analyser (Beckman Synchron 
LX20, Beckman Coulter Inc., Brea, USA) and multiplied by collection volume to 
obtain the 24-hour urinary albumin excretion. Urinary albumin concentration below 
the detection limit of the assay (2 mg/l), the urinary albumin concentration was set at 
1.5 mg/l before multiplying by collection volume. Only urine collections with a 
collection time between 20 and 28 hours were considered valid. If needed, urinary 
albumin excretion was extrapolated to a 24-hours’ excretion. Microalbuminuria was 
defined as a urinary albumin excretion of 30-300 mg per 24 hours whereas 
macroalbuminuria was defined as a urinary albumin excretion of > 300 mg per 24 
hours 6. These definitions were preferably based on the average of two (90%) 24-
hour urine collections. 
 
Covariates 
As described previously 7, fasting venous blood samples were used to assess total 
cholesterol, LDL and HDL cholesterol, triglycerides, creatinine and HbA1c. Serum 
total cholesterol, HDL cholesterol, triglycerides, albumin and serum and urine 
creatinine and uric acid levels were measured with standard (enzymatic and/or 
colorimetric) methods by an automatic analyzer (Beckman Synchron LX20, Beckman 
Coulter Inc., Brea, USA). LDL cholesterol was calculated according to the Friedewald 
formula 8. Serum creatinine was measured with a Jaffé method traceable to isotope 
dilution mass spectrometry (Beckman Synchron LX20, Beckman Coulter Inc., Brea, 
USA). Glomerular filtration rate (eGFR) was estimated using the CKD-EPI (Chronic 
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Kidney Disease Epidemiology Collaboration) equation based on serum creatinine 9. 
HbA1c was measured with ion-exchange high performance liquid chromatography 
(HPLC) (Variant tm II, Bio-Rad, Hercules, California, USA). Urinary albumin was 
measured with a immunoturbidimetric assay (Cobas c systems, Roche diagnostics, 
Mannheim, Germany). Waist circumference was measured in duplicate midway 
between the lower rib margin and the iliac crest at the end of expiration, to the 
nearest 0.5 cm, with a flexible plastic tape measure (Seca, Hamburg, Germany). 
Participants were requested to bring all the medication they used at the time of 
measurement or a list from their pharmacists to the research center. During a 
medication interview generic name, dose and frequency, and additional over-the-
counter (OTC) medication use were registered by trained staff. All participants 
received extensive web-based questionnaires. Duration of diabetes was assessed by 
using the year of diagnosis reported in the questionnaire. Smoking status (never, 
former, current) was based on smoking cigarettes, cigars and/or pipe tobacco. 
History of cardiovascular disease was assessed with a modified version of the Rose 
Questionnaire for the diagnosis of ischemic heart pain and intermittent claudication 10  
and defined as self-reported myocardial infarction, and/or cerebrovascular infarction 
or hemorrhage, and/or percutaneous artery angioplasty of, or vascular surgery on, 
the coronary arteries, abdominal arteries, peripheral arteries or carotid arteries. Office 
blood pressure was determined three times on the right arm after a 10-minute rest 
period, using a non-invasive blood pressure monitor (Omron 705IT, Japan). 
Hypertension was defined as office systolic blood pressure >140 mmHg, diastolic 
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Supplementary Table S1. General characteristics of the Maastricht Study participants 
by glucose metabolism status. 










NGM/IGM/T2DM (%) - - - - 
Age (years) 57 ± 9 62 ± 8 64 ± 7 <0.001 
Sex (number of males/females) 213/256 83/57 176/77 <0.001 
Diabetes duration (y) - - 7 [3-11]  - 
HbA1c (%) 5.6 ± 0.3 5.9 ± 0.4 6.9 ± 0.9 <0.001 
HbA1c (mmol/mol) 38 ± 4 41 ± 4 52 ± 10 <0.001 
Smoking, never/former/current (%) 36/46/18 28/57/15 22/64/14 <0.001 
Waist circumference (cm) 92 ± 11 99 ± 12 106 ± 13 <0.001 
Total-to-HDL cholesterol ratio 4.1 ± 1.3 4.4 ± 1.3 4.2 ± 1.2 0.003 
Triglycerides (mmol/L) 1.0 [0.8-1.5] 1.4 [1.0-2.1] 1.7 [1.2-2.3] <0.001 
eGFRCKD-EPI (ml/min/1.73m2) 87 ± 14 82 ± 13 82 ± 16 0.002 
Albuminuria (normo/micro/macro) (%) 96/3/1 93/6/1 83/16/1 <0.001 
Peripheral sensory neuropathy (n (%)) 31 (6) 10 (10) 39 (22) <0.001 
Hypertension (n (%)) 189 (40) 92 (66) 219 (87) <0.001 
Anti-hypertensive medication (n (%)) 102 (22) 62 (44) 182 (72) <0.001 
Lipid lowering medication (n (%)) 76 (16) 51 (36) 191 (76) <0.001 
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Diabetes medication (n (%)) 0 0 198 (78) <0.001 
History of CVD (n (%)) 53 (12) 25 (18) 73 (31) <0.001 
SAF (AU) 2.58 ± 0.49 2.70 ± 0.45 2.95 ± 0.57 <0.001 
Pentosidine (nmol/mmol LYS) 0.48 [0.39-0.58] 0.44 [0.38-0.54] 0.45 [0.35-0.57] 0.057 
CML (nmol/mmol LYS) 77.2 ± 14.2 72.3 ± 14.1 70.0 ± 14.7 <0.001 
CEL (nmol/mmol LYS) 32.8 ± 9.3 34.4 ± 10.5 36.3 ± 11.3 0.002 
cfPWV (m/s) 8.37 ± 1.77 9.32 ± 1.96 9.96 ± 2.47 <0.001 
MAP (mmHg) 96 ± 11 100 ± 10 99 ± 9 0.001 
Heart rate (bpm) 62 ± 8 63 ± 9 66 ± 10 <0.001 
Central pulse pressure (mmHg) 43 [35-53] 47 [38-58] 50 [40-64] <0.001 
Ambulatory 24h PP (mmHg) 43 ± 7 47 ± 9 50 ± 10 <0.001 
Ambulatory 24h MAP (mmHg) 91 ± 8 95 ± 10 94 ± 8 <0.001 
Ambulatory 24h heart rate (bpm) 69 ± 8 70 ± 9 71 ± 10 0.017 
 
Data are presented as mean ± standard deviation (SD) or as median [inter quartile range 
(IQR)], unless otherwise indicated.  
NGM, normal glucose metabolism; IGM, impaired glucose metabolism; T2DM, type 2 
diabetes; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; eGFRCKD-EPI, 
estimated Glomerular Filtration Rate; SBP, systolic blood pressure; DBP, diastolic blood 
pressure; cfPWV, carotid to femoral pulse wave velocity; MAP, mean arterial pressure; 
CVD, cardiovascular disease; SAF, skin autofluorescence; CML, N(epsilon)-






Supplementary Table S2. Associations between measures of AGE 





24-hour pulse pressure 
Model sβ 95% CI p-value 
SAF 1 0.05 -0.02 – 0.13 0.160 
 2 0.06 -0.01 – 0.12 0.079 
 3 0.06 -0.01 – 0.12 0.085 
Plasma pentosidine 1 0.07 0.00 – 0.13 0.043 
 2 0.06 0.01 – 0.12 0.033 
 3 0.05 -0.01 - 0.11 0.089 
Plasma CML 1 0.05 -0.01 – 0.12 0.102 
 2 0.07 0.01 – 0.13 0.016 
 3 0.06 -0.01 - 0.12 0.078 
Plasma CEL 1 0.01 -0.05 – 0.08 0.661 
 2 0.01 -0.05 – 0.07 0.771 
 3 0.03 -0.03 – 0.09 0.304 
 
Standardized β, the standardized regression coefficient obtained with linear regression 
analyses, indicates the change in 24-hour ambulatory pulse pressure (aPP) (in SD) 
per 1 SD higher skin autofluorescence (SAF) or level of plasma advanced glycation 
endproducts, i.e. plasma pentosidine, CML (N(epsilon)-(carboxymethyl)lysine) and 
CEL (N(epsilon)-(carboxyethyl)lysine).  
Model 1 is adjusted for age, sex and glucose metabolism status. Model 2 is 
additionally adjusted for average mean arterial pressure*. Model 3 is additionally 
adjusted for average heart rate*, waist circumference, smoking, antihypertensive, lipid-
modifying and diabetes medication use, eGFR, total-to-HDL-cholesterol ratio, 
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triglycerides and a history of cardiovascular disease.  
There were 696 individuals (389 with NGM, 114 with IGM and 193 with T2DM) 
included in the analyses between SAF and aPP, and 712 individuals (394 with NGM, 
119 with IGM and 199 with T2DM) in the analyses between plasma AGEs and aPP. 
* In analyses with aPP, average mean arterial pressure and heart rate obtained from 





Supplementary Table S3. Associations between measures of AGE accumulation 
and measures of arterial stiffness with and without additional adjustment for 
peripheral sensory neuropathy and albuminuria. 
AGEs 
 
Carotid to femoral  
pulse wave velocity  
 Central pulse pressure 
Model sβ 95% CI 
p-
value 
 sβ 95% CI p-value 
SAF 1 0.09 0.02 – 0.17 0.017  0.10 0.02 – 0.18 0.015 
 2 0.09 0.02 – 0.17 0.017  0.10 0.02 – 0.19 0.013 
Plasma pentosidine 1 0.05 -0.02 – 0.13 0.139  0.09 0.02 – 0.17 0.015 
 2 0.06 -0.02 – 0.13 0.127  0.09 0.02 – 0.17 0.013 
Plasma CML 1 0.01 -0.07 – 0.08 0.827  0.05 -0.03 – 0.12 0.244 
 2 0.01 -0.06 – 0.08 0.827  0.05 -0.03 – 0.12 0.237 
Plasma CEL 1 0.02 -0.04 – 0.09 0.512  0.02 -0.05 – 0.09 0.526 
 2 0.02 -0.04 – 0.09 0.498  0.02 -0.05 – 0.09 0.521 
 
Standardized β, the standardized regression coefficient obtained with linear regression 
analyses, indicates the change in carotid to femoral pulse wave velocity (cfPWV) or 
central pulse pressure (cPP) (in SD) per 1 SD higher skin autofluorescence (SAF) or 
level of plasma advanced glycation endproducts, i.e. plasma pentosidine, CML 
(N(epsilon)-(carboxymethyl)lysine) and CEL (N(epsilon)-(carboxyethyl)lysine).  
Model 1 is adjusted for age, sex and glucose metabolism status, average mean 
arterial pressure, average heart rate, waist circumference, smoking, antihypertensive 
and lipid-lowering medication use, eGFR, total-to-HDL-cholesterol ratio, triglycerides 
and a history of cardiovascular disease. Model 2 is additionally adjusted for peripheral 
sensory neuropathy (PSN) and albuminuria. 
There were 547 individuals included in the analyses between SAF and cfPWV, 555 
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individuals in the analyses between plasma AGEs and cfPWV, 536 individuals in the 
analyses between SAF and cPP, and 545 individuals in the analyses between plasma 
AGEs and cPP. 
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Supplementary Figure S1. Associations between measures of AGE accumulation 
and measures of arterial stiffness in the total population and in the population 
without prior cardiovascular disease. 
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Data are presented as standardized β (sβ) and 95%-confidence interval. sβ is the 
standardized regression coefficient obtained with linear regression analyses, which 
indicates the change in carotid to femoral pulse wave velocity (cfPWV) or central 
pulse pressure (cPP) (in SD) per 1 SD higher skin autofluorescence (SAF) or level of 
plasma pentosidine. 
The presented sβ’s are adjusted for age, sex, glucose metabolism status, average 
mean arterial pressure and heart rate, waist circumference, smoking, 
antihypertensive and lipid-modifying medication use, eGFR, total-to-HDL-cholesterol 
ratio and triglycerides. 
For the analyses in the total population, there were 740 individuals included in the 
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analyses between SAF and cfPWV, 752 individuals in the analyses between plasma 
AGEs and cfPWV, 726 individuals in the analyses between SAF and cPP and 739 in 
the analyses between plasma AGEs and cPP. For the analyses in the population 
without prior CVD, there were 611 individuals included in the analyses between SAF 
and cfPWV, 622 individuals in the analyses between plasma AGEs and cfPWV, 599 
individuals in the analyses between SAF and cPP, and 611 individuals in the 
analyses between plasma AGEs and cPP. 
